| Bioactivity | Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptarelin doxorubicin has been used to research targeting tumors expressing LHRH receptors. Zoptarelin doxorubicin abolishes tumor progression and induces remarkable apoptosis in vitro[1]. |
| Invitro | Zoptarelin doxorubicin (AN-152) inhibits almost 70 % of glioblastoma cell growth, increases almost 250% apoptosis and causes a greater increase in calcein retention[1].Zoptarelin doxorubicin (AN-152) up-regulates the tumor suppressor and pro-apoptotic p53, and inhibits the expression of the primordial, neuroectodermal stem cell marker, nestin[1]. Cell Proliferation Assay[1] Cell Line: |
| Name | Zoptarelin doxorubicin |
| CAS | 139570-93-7 |
| Formula | C91H117N19O26 |
| Molar Mass | 1893.01 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Zoptarelin doxorubicin
CAS: 139570-93-7 F: C91H117N19O26 W: 1893.01
Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptareli
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.